Document:

EX-10.1

 EXHIBIT 10.1 

AMENDMENT NO. 3 TO CREDIT AGREEMENT 

This Amendment No. 3 to Credit Agreement (“Amendment”) is made as of April 22, 2014 (“Third
Amendment Effective Date”) among MANITEX INTERNATIONAL, INC., a Michigan corporation, MANITEX, INC., a Texas corporation, MANITEX SABRE, INC., a Michigan corporation, BADGER EQUIPMENT COMPANY, a Minnesota
corporation, and MANITEX LOAD KING, INC., a Michigan corporation (each, individually a “US Borrower,” and collectively the “US Borrowers”) and MANITEX LIFTKING, ULC, an Alberta company (the
“Canadian Borrower” and, together with the US Borrowers, the “Borrowers” and each individually, a “Borrower”) and COMERICA BANK, a Texas banking association (in its individual capacity,
“Comerica”), as US Agent, US Swing Line Lender, a US Issuing Lender and a US Lender, COMERICA BANK, a Texas banking association and authorized foreign bank under the Bank Act (Canada), through its Toronto branch (in
its individual capacity, “Comerica Canada”) as Canadian Agent, Canadian Swing Line Lender, Canadian Issuing Lender and a Canadian Lender, and all other Lenders from time to time party hereto (collectively, the
“Lenders”). 
 PRELIMINARY STATEMENT 

The Borrowers, US Agent, Canadian Agent and the Lenders entered into a Credit Agreement dated August 19, 2013, as amended
by that First Amendment to Credit Agreement dated as of October 15, 2013 and that Second Amendment to Credit Agreement dated as of November 26, 2013 (as amended the “Credit Agreement”) providing terms and conditions
governing certain loans and other credit accommodations extended by the US Agent, Canadian Agent and Lenders to Borrowers (“Obligations”). 

Borrowers, US Agent, Canadian Agent and the Lenders have agreed to amend the terms of the Credit Agreement as provided in this
Amendment. 
 AGREEMENT 

1. Defined Terms. In this Amendment, capitalized terms used without separate definition shall have the meanings given
them in the Credit Agreement. 
 2. Amendment. 

a. The following definition of “Canadian WIP Cap” is hereby added to Section 1.1 of the Credit Agreement in the
appropriate alphabetical order: 
 “Canadian WIP Cap shall mean (i) CDN$1,000,000 from the
Third Amendment Effective Date through to March 31, 2015, and (ii) CDN$850,000 from April 1, 2015 and thereafter. 

b. The following definition of “Canadian Inventory Cap” is hereby added to Section 1.1 of the Credit Agreement
in the appropriate alphabetical order: 
 “Canadian Inventory Cap shall mean
(i) CDN$7,000,000 from the Third Amendment Effective Date through to March 31, 2015, and (ii) CDN$5,500,000 from April 1, 2015 and thereafter. 

 c. The following definition of “Third Amendment Effective Date” is
hereby added to Section 1.1 of the Credit Agreement in the appropriate alphabetical order: 
 d. “Third
Amendment Effective Date shall mean April 22, 2014. 
 e. The definition of “Canadian Borrowing Base” in
Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows: 

“Canadian Borrowing Base shall mean, as of any date of determination thereof, without duplication,
an amount equal to the sum of: 
 (a) eighty-five percent (85%) of Canadian Borrowing Base
Obligors’ Eligible Accounts; plus 
 (b) eighty-five percent (85%) of Canadian Borrowing Base
Obligors’ Eligible Government Accounts; plus 
 (c) the sum of (x) 50% of Canadian Borrowing Base
Obligors’ Eligible Inventory (excluding work-in-process Eligible Inventory); plus (y) the lesser of (i) 30% of Canadian Borrowing Base Obligors’ work-in-process Eligible Inventory which is properly classified under GAAP as
work-in-process inventory, or (ii) the Canadian WIP Cap; provided, however, the sum of amounts determined under (x) plus the amount determined under (y) shall not exceed the Canadian Inventory Cap; minus 

(d) Priority Payables; 

provided that (x) the Canadian Borrowing Base shall be determined on the basis of the most current
Canadian Borrowing Base Certificate required or permitted to be submitted hereunder, and (y) any reserves or other adjustments established by the Canadian Agent or the Majority Canadian Revolving Credit Lenders on the basis of any subsequent
collateral audits conducted hereunder, all in accordance with ordinary and customary asset-based lending standards, as reasonably determined by the Canadian Agent and the Majority Canadian Revolving Credit Lenders. For greater certainty, Canadian
Borrowing Base Obligors’ Eligible Accounts and Eligible Inventory shall not include inventory financed pursuant to the Specialized Equipment Export Facility and accounts derived therefrom and provided, further such inventory financed by the
Specialized Equipment Export Facility and accounts derived therefrom shall be detailed in a schedule to the Canadian Borrowing Base Certificate.” 

f. The definition of “Eligible Canadian Accounts” in Section 1.1 of the Credit Agreement is hereby replaced by
the following definition of “Eligible Government Accounts”: 
 “Eligible Government
Accounts shall mean those Accounts which meet all the requirements of Eligible Accounts except for the requirements set forth in (j)(ii) of the definition of Eligible Accounts and shall include the following government Accounts owing by:
(i) Canadian Commercial Corporation, a Crown corporation of the Government of Canada, (ii) Canadian Department of National Defence, a department of the Government of Canada, (iii) the US State Department – GSO, (iv) the USA
CE Finance Center, (v) the United Nations, and (vi) North Atlantic Treaty Organization (NATO).” 

  
 - 2 - 

 3. Representations and Warranties. The Borrowers represent, warrant, and
agree that: 
 a. Except as expressly modified in this Amendment, the representations, warranties, and covenants set forth
in the Credit Agreement and in each related document, agreement, and instrument remain true and correct, continue to be satisfied in all respects, and are legal, valid and binding obligations with the same force and effect as if entirely restated in
this Amendment, other than those representations and warranties that expressly relate solely to a specific earlier date, which shall remain correct as of such earlier date. 

b. When executed, the Agreement, as amended by this Amendment will continue to constitute a duly authorized, legal, valid, and
binding obligation of the Borrowers enforceable in accordance with its terms. The Credit Agreement, as amended, along with each related document, agreement and instrument, is ratified and confirmed and shall remain in full force and effect and the
Credit Parties further represent and warrant that they have taken all actions necessary to authorize the execution and performance of such documents. 

c. There is no Default or Event of Default existing under the Credit Agreement, or any related document, agreement, or
instrument, and no event has occurred or condition exists that is or, with the giving of notice or lapse of time or both, would be such a default. 

d. As applicable to each such Credit Party, the articles of incorporation, articles of formation, articles of amalgamation,
bylaws, operating agreements and resolutions and incumbency certificates of the Borrowers and the Guarantors delivered to US Agent and Canadian Agent in connection with the Credit Agreement on or about August 19, 2013, have not been repealed,
amended or modified since the date of delivery thereof and that same remain in full force and effect. 
 4. Successors
and Assigns. This Amendment shall inure to the benefit of and be binding upon the parties and their respective successors and assigns. 

5. Governing Law. The parties agree that the terms and provisions of this Amendment shall be governed by and construed
in accordance with the laws of the State of Michigan without regard to principles of conflicts of law. 
 6. No
Defenses. The Credit Parties acknowledge, confirm, and warrant to US Agent, Canadian Agent and the Lenders that as of the date hereof the Credit Parties have absolutely no defenses, claims, rights of set-off, or counterclaims against US Agent,
Canadian Agent and the Lenders under, arising out of, or in connection with, this Amendment, the Credit Agreement, the Loan Documents and/or the individual advances under the Obligations, or against any of the indebtedness evidenced or secured
thereby. 
 7. Ratification. Except for the modifications under this Amendment, the parties ratify and confirm the
Credit Agreement and the Loan Documents and agree that they remain in full force and effect. 
 8. Further Modification;
No Reliance. This Amendment may be altered or modified only by written instrument duly executed by the Credit Parties and the Lenders. In executing this Amendment, the Credit Parties are not relying on any promise or commitment of US Agent,
Canadian Agent and/or the Lenders that is not in writing signed by the applicable Agent and/or the Lenders. 

  
 - 3 - 

 9. Acknowledgment and Consent of Guarantors. Each of the US Credit Parties
has guaranteed the payment and performance of the Obligations by Borrowers pursuant to Guaranty dated August 19, 2013 (the “Guaranty”). Each of the Guarantors, by singing below, acknowledges and consents to the execution, delivery and
performance of this Amendment, and agrees that the Guaranty remains in full force and effect. Each of the Guarantors further represents that it is in compliance with all of the terms and conditions of its Guaranty. 

10. Expenses. Borrowers shall promptly pay all out-of-pocket fees, costs, charges, expenses, and disbursements of US
Agent, Canadian Agent and the Lenders incurred in connection with the preparation, execution, and delivery of this Amendment, and the other documents contemplated by this Amendment. 

11. Effectiveness and Counterparts. This Amendment may be executed in as many counterparts as US Agent, Canadian Agent,
the Lenders and the Borrowers deem convenient, and shall become effective upon delivery to US Agent and Canadian Agent of: (i) all executed counterparts hereof from the Lenders and from Borrowers and each of the Guarantors; (ii) the
documents listed on the Closing Checklist attached hereto as Exhibit A; and (iii) any other documents or items which US Agent or Canadian Agent may require to carry out the terms hereof. 

  
 - 4 - 

 This Amendment No. 3 to Credit Agreement is executed and delivered on the
Third Amendment Effective Date. 
  

			
	 COMERICA BANK, as US Agent

		
	 By:
	 	 /s/ James Q. Goudie, III

		 	 James Q. Goudie, III

	 Its:
	 	 Vice President

  

			
	 COMERICA BANK, as US Lender, as US Issuing Lender, and as US Swing Line Lender

		
	 By:
	 	 /s/ James Q. Goudie, III

		 	 James Q. Goudie, III

	 Its:
	 	 Vice President

  

			
	 COMERICA BANK, as Canadian Agent

		
	 By:
	 	 /s/ Omer Ahmed

		 	 Omer Ahmed

	 Its:
	 	 Portfolio Manager

  

			
	 COMERICA BANK, as Canadian Lender, as Canadian Issuing Lender, and as Canadian Swing Line Lender

		
	 By:
	 	 /s/ Omer Ahmed

		 	 Omer Ahmed

	 Its:
	 	 Portfolio Manager

  
 - 5 - 

 [Signature Page – US Lender] 

 

			
	 FIFTH THIRD BANK, as US Lender

	
	 /s/ Matthew Berman

		
	 By:
	 	 Matthew Berman

		 	 Print Name

	 Its:
	 	 Assistant Vice President

		 	 Title

  
 - 6 - 

 [Signature Page – US Lender] 

 

			
	 HSBC BANK USA, N.A, as US Lender

	
	 /s/ Daniel K. Sabol

		
	 By:
	 	 Daniel K. Sabol

		 	 Print Name

		
	 Its:
	 	 Vice President

		 	 Title

  
 - 7 - 

 [Signature Page US Borrowers] 

 

			
	MANITEX INTERNATIONAL, INC.
		
	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke

	 Its:
	 	 President

	
	MANITEX, INC.
		
	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke

	 Its:
	 	 President

	
	MANITEX SABRE, INC.
		
	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke

	 Its:
	 	 Vice President

	
	BADGER EQUIPMENT COMPANY
		
	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke

	 Its:
	 	 Vice President

	
	MANITEX LOAD KING, INC.
		
	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke

	 Its:
	 	 Vice President

  
 - 8 - 

 [Signature Page Canadian Borrower] 

 

			
	MANITEX LIFTKING, ULC
		
	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke

	 Its:
	 	 Vice President

  
 - 9 - 

 [Signature Page US Guarantors] 

 

									
	 GUARANTORS:
	 		 		 	
			
	 MANITEX INTERNATIONAL, INC.
	 		 	 MANITEX, INC.

					
	 By:
	 	 /s/ Andrew M. Rooke
	 		 	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke
	 		 		 	 Andrew M. Rooke

	 Its:
	 	 President
	 		 	 Its:
	 	 President

			
	 MANITEX SABRE, INC.
	 		 	 BADGER EQUIPMENT COMPANY

					
	 By:
	 	 /s/ Andrew M. Rooke
	 		 	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke
	 		 		 	 Andrew M. Rooke

	 Its:
	 	 Vice President
	 		 	 Its:
	 	 Vice President

			
	 MANITEX LOAD KING, INC.
	 		 	 LIFTKING, INC.

					
	 By:
	 	 /s/ Andrew M. Rooke
	 		 	 By:
	 	 /s/ Andrew M. Rooke

		 	 Andrew M. Rooke
	 		 		 	 Andrew M. Rooke

	 Its:
	 	 Vice President
	 		 	 Its:
	 	 President

				
	 MANITEX, LLC
	 		 		 	
					
	 By:
	 	 /s/ Andrew M. Rooke
	 		 		 	
		 	 Andrew M. Rooke
	 		 		 	
	 Its:
	 	 Vice President
	 		 		 	

  
 - 10 - 

 EXHIBIT “A” 

CLOSING CHECKLIST 
  

			
	 US Borrowers:
	  	 Manitex International, Inc., a Michigan corporation

Manitex, Inc. a Texas corporation

Manitex Sabre, Inc., a Michigan corporation

Badger Equipment Company, a Minnesota corporation

Manitex Load King, Inc., a Michigan corporation

		
	 Canadian Borrower:
	  	 Manitex Liftking, ULC, an Alberta corporation

		
	 Agent:
	  	 Comerica Bank, as US Agent for all Lenders

Comerica Bank, as Canadian Agent for all Canadian Lenders

		
	 Lenders:
	  	 Comerica Bank, as US Lender and Canadian Lender

HSBC Bank, N.A., as US Lender

Fifth Third Bank, as US Lender

		
	 Guarantors:
	  	 Liftking, Inc. (with respect to debt of US Borrowers and Canadian Borrower)

Manitex, LLC (with respect to debt of Canadian Borrower)

All US Borrowers (with respect to debt of Canadian Borrower)

		
	 Transaction:
	  	 Amendment No. 3 to Credit Agreement

 LOAN DOCUMENTS 
  

	 	1.	 Amendment No. 3 to Credit Agreement 

	 	2.	 Closing Certificate 

  
 - 11 -EX-10.1

 Exhibit 10.1 
  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Amendment No. 2 to the 

Respiratory Diseases Research Collaboration and License Agreement 

This Amendment No. 2 to the Respiratory Diseases Research Collaboration and License Agreement (this “Amendment No. 2”), effective
as of April 9, 2014 (the “Amendment No. 2 Effective Date”), is made by and between Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road,
Brentford, Middlesex, TW8 9GS, England (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080 (“FivePrime”). 

Recitals: 
 WHEREAS,
FivePrime and GSK are parties to the Respiratory Diseases Research Collaboration and License Agreement, effective April 11, 2012, as amended effective August 9, 2012 (as amended, the “Collaboration Agreement”), under which
GSK and FivePrime entered into a research collaboration to use FivePrime’s proprietary technology to identify and advance targets involved in respiratory diseases; 

WHEREAS, pursuant to Section 13.7 of the Collaboration Agreement, the Collaboration Agreement may be amended only by a written instrument
duly executed by authorized representatives of both GSK and FivePrime; and 
 WHEREAS, GSK and FivePrime desire to amend the Collaboration
Agreement as set forth in this Amendment No. 2. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
contained in this Amendment No. 2, the receipt and sufficiency of which are hereby acknowledged, FivePrime and GSK hereby agree as follows: 

1. Defined Terms. Capitalized terms used in this Amendment No. 2 and not defined herein shall have the respective meanings set forth in the
Collaboration Agreement. 
 2. Expansion of Research Program to Include Additional Screening Assays. Section 3.2.2 of the Collaboration
Agreement is hereby amended to add the following sentences to the end of such Section 3.2.2: 
 “In accordance with
Section 2.2.2, to the extent that the Parties mutually agree that an un-performed Screening Assay(s) would not be scientifically feasible to perform, then the JSC may agree to modify the Research Plan to substitute any un-performed Screening
Assay, including any additional Screening Assay elected pursuant to this Section 3.2.2 (other than a Terminated Assay). Further, GSK may, at any time within six (6) months following the date of its delivery to FivePrime of an Expansion
Notice with respect to an 

 
additional Screening Assay pursuant to this Section 3.2.2, terminate the conduct of all activities under the Research Plan with respect to such additional Screening Assay (each such
terminated Screening Assay, a “Terminated Assay”) by providing FivePrime written notice of such termination (a “Termination Notice”). Promptly following its receipt of a Termination Notice, FivePrime shall cease all
activities with respect to the Terminated Assay, and the Parties shall negotiate in good faith an amendment of the Research Plan to remove all activities with respect to the conduct of such Terminated Assay; provided that such amendment shall
be solely for the purpose of removing from the Research Plan the activities with respect to the conduct of such Terminated Assay and shall not include any reduction to the payments GSK is or would be obligated to make to FivePrime pursuant to the
terms of this Agreement, save as set out in Section 6.2.2.” 
 3. Research Program Funding for Additional Assays. Section 6.2.2 of the
Collaboration Agreement is hereby amended and restated in its entirety, to read as follows: 
 “6.2.2 Research Program Funding for
Additional Assays. In consideration for FivePrime’s performance of any additional Screening Assays GSK elects to include in the Research Program pursuant to Section 3.2.2, GSK shall pay to FivePrime (a) *** for each such Screening
Assay that is a ***; and (b) one million dollars ($1,000,000) for each such Screening Assay that is a ***. Such payment(s) shall be made in eight equal installment payments after the date on which GSK delivers the relevant Expansion Notice, as
follows: (i) promptly after receipt of an Expansion Notice FivePrime shall Invoice GSK, and GSK shall pay to FivePrime within *** days following receipt of such Invoice by GSK, the first installment payment and (ii) thereafter GSK shall
pay to FivePrime the remaining seven installment payments on a Calendar Quarter basis. It is the intent of the Parties that GSK will pay each installment payment under this Section 6.2.2, other than the first installment payment, on the first
day of each Calendar Quarter starting with the first (1st) Calendar Quarter after the date on which GSK delivered the relevant Expansion Notice to FivePrime and that FivePrime may,
accordingly, Invoice GSK for each such quarterly payment *** days in advance of the start of a Calendar Quarter; provided, however, that GSK shall have no obligation to pay any such Invoiced amounts in less than *** days following
receipt of such Invoice. Notwithstanding the foregoing, if GSK shall deliver a Termination Notice with respect to any additional Screening Assay, GSK shall have no obligation to pay any additional installment payment that becomes due with respect to
such additional Screening Assay after the date such Screening Assay becomes a Terminated Assay. For clarity, the maximum amount GSK may be required to pay under this Section 6.2.2 shall be ***, in the event that GSK elects to expand the
Research Program to include *** and neither of such *** becomes a Terminated Assay.” 

  
 2 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 4. Research Program Funding for Substituted Screening Assays. A new Section 6.2.2.A shall be inserted
into the Collaboration Agreement to read as follows: 
 “6.2.2.A Research Program Funding for Substituted Screening Assays. In
the event that a *** is substituted for an alternative *** pursuant to Section 2.2.2, then from the date on which the JSC agrees that the *** shall be substituted, the payments remaining from GSK after the date of such substitution in respect
of such substituted *** shall be reduced to the amount that GSK would have paid to FivePrime if such *** had been originally selected by GSK (and no adjustment or reimbursement shall be made in respect of payments already made by GSK). The Parties
acknowledge that (i) there would be no change to the payments in the event of a substitution from one *** to an alternative ***; and (ii) a substitution from a *** to a *** does not fall within the remit of the JSC pursuant to
Section 2.2.2, and any such substitution would require the written agreement of the Parties.” 
 5. Miscellaneous Provisions;
Incorporation by Reference. 
 5.1. GSK Registered Office. The Parties acknowledge and agree that GSK’s registered office
(but not its address for notice purposes under Section 13.4 of the Collaboration Agreement) has changed to 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. Section 13.4 of the Collaboration Agreement remains unchanged.

 5.2. Entire Agreement. The Collaboration Agreement as amended by this Amendment No. 2 constitutes the entire understanding of
GSK and FivePrime with respect to the subject matter thereof and supersedes and cancels all other previous express or implied agreements. 

5.3. Governing Law. This Amendment No. 2 shall be governed by and construed in accordance with the laws of the State of Delaware
without reference to any rules of conflict of laws. 
 5.4. Counterparts. This Amendment No. 2 may be executed in one (1) or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment No. 2 may be executed by facsimile or electronic signatures, which signatures shall have the
same force and effect as original signatures. 
 5.5. Modification. This Amendment may not be modified or amended in any way unless
done so in accordance with Section 13.7 of the Collaboration Agreement. 
 5.6. Full Force and Effect of Collaboration Agreement.
This Amendment No. 2 is effective as of the Amendment No. 2 Effective Date. Except as expressly set forth in this Amendment No. 2, the Collaboration Agreement shall remain in full force and effect except that reference to the
“Agreement” or words of like import in the Collaboration Agreement will mean and will be a reference to the Collaboration Agreement as amended by this Amendment No. 2. 

  
 3 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 [Remainder of page intentionally blank; signature page follows] 

  
 4 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 IN WITNESS WHEREOF, FivePrime and GSK have executed this Amendment No. 2 as of the Amendment No.
2 Effective Date. 
  

									
	Glaxo Group Limited	 		 	Five Prime Therapeutics, Inc.
					
	BY:	 	 /s/ Olaf Ulrich
	 		 	BY:	 	 /s/ Lewis T. Williams

		 	 Name: Olaf Ulrich
 Title: Alliance
Director
	 		 		 	 Name: Lewis T. Williams
 Title: President and
Chief Executive Officer

  
 5 

  

	***	INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]